ArticleFrontiers in microbiology2021
Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Meta-analysis of the human upper respiratory tract microbiome reveals robust taxonomic associations with health and disease.BMC biology · 2024Pooled it
- Human microbiota dysbiosis after SARS-CoV-2 infection have the potential to predict disease prognosis.BMC infectious diseases · 2023Pooled it
- COVID-19 alters human microbiomes: a meta-analysis.Frontiers in cellular and infection microbiology · 2023Pooled it
- Gut microbial profiles of COVID-19 patients in Uganda.African health sciences · 2026Article
- SARS-CoV-2 lineages and naso-oropharyngeal bacterial communities in COVID-19 reinfection: A study in West Java, Indonesia.Narra J · 2025Article
- Oral microbiota and respiratory diseases: advances and perspectives.Clinical microbiology reviews · 2025Review
- Impact of SARS-CoV-2 P.1 Variant Infection on the Nasopharyngeal Commensal Bacterial Microbiome of Individuals from the Brazilian Amazon.Microorganisms · 2025Article
- Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression.Journal of microbiology (Seoul, Korea) · 2024Review
- Insights into the Naso-Oropharyngeal Bacterial Composition in Suspected SARS-CoV-2 Cases.Pathogens (Basel, Switzerland) · 2024Article
- Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities.Microbiology spectrum · 2024Article
- Oropharyngeal Microbiome Analysis in Patients with Varying SARS-CoV-2 Infection Severity: A Prospective Cohort Study.Journal of personalized medicine · 2024Article
- Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection.Archives of Iranian medicine · 2024Article
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
- Comparative analysis of oropharyngeal microbiota in healthcare workers post-COVID-19.Frontiers in cellular and infection microbiology · 2024Article
- Integrated analysis reveals important differences in the gut and oropharyngeal microbiota between children with mild and severe hand, foot, and mouth disease.Emerging microbes & infections · 2023Article
- The nasopharyngeal microbiome in COVID-19.Emerging microbes & infections · 2023Article
- Bacterial Biomarkers of the Oropharyngeal and Oral Cavity during SARS-CoV-2 Infection.Microorganisms · 2023Article
- Disentangling the interactions between nasopharyngeal and gut microbiome and their involvement in the modulation of COVID-19 infection.Microbiology spectrum · 2023Article
- Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + .Scientific reports · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoV-2 is an RNA virus causing COVID-19. The clinical characteristics and epidemiology of COVID-19 have been extensively investigated, however, only one study so far focused on the patient's nasopharynx microbiota. In this study we investigated the nasopharynx microbial community of patients that developed different severity levels of COVID-19. We performed 16S ribosomal DNA sequencing from nasopharyngeal swab samples obtained from SARS-CoV-2 positive (56) and negative (18) patients in the province of Alicante (Spain) in their first visit to the hospital. Positive SARS-CoV-2 patients were observed and later categorized in mild (symptomatic without hospitalization), moderate (hospitalization), and severe (admission to ICU). We compared the microbiota diversity and OTU composition among severity groups and built bacterial co-abundance networks for each group.
resultsStatistical analysis indicated differences in the nasopharyngeal microbiome of COVID19 patients. 62 OTUs were found exclusively in SARS-CoV-2 positive patients, mostly classified as members of the phylum Bacteroidota (18) and Firmicutes (25). OTUs classified as
conclusionOur study shows that the nasopharyngeal microbiome of COVID-19 patients showed differences in the composition of specific OTUs and complexity of co-abundance networks. Taxa with differential abundances among groups could serve as biomarkers for COVID-19 severity. Nevertheless, further studies with larger sample sizes should be conducted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.